Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P230011/S008

TruSight Oncology Comprehensive

Illumina, Inc. · Decision date Sep 4, 2026

MEDTECHLEDGER EXPLANATIONP230011/S008

What did the FDA decide?

FDA posted a decision dated 2026-09-04 for supplement S008 to PMA P230011, TruSight Oncology Comprehensive from Illumina, Inc. The decision code is OK30, and the supplement type is a 30-Day Notice. The stated reason is a process change involving manufacturer, sterilizer, packager, or supplier, and the statement describes a supplier manufacturing site change.

This notice does not represent a new approval of the whole system or a new indication. The database fields do not state which supplier, which manufacturing site, or what specific manufacturing activity changed. The device is categorized as a next generation sequencing oncology panel, somatic or germline variant detection system under product code PQP and pathology specialty.

FDA approval order statement

a supplier manufacturing site change
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Pathology
Decision date
Sep 4, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P230011/S008
Regulatory pathway
PMA supplement
Product code
PQP
Decision code
OK30
Decision date
Sep 4, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Next generation sequencing oncology panel, somatic or germline variant detection system.

Product code
PQP
FDA device class
3

For the original device and its historical approval scope, see PMA P230011. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P230011 · Original PMA

    TruSight Oncology Comprehensive

  2. P230011/S008 received

    Application receipt date recorded by FDA.

  3. P230011/S008 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P230011. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P230011

Product / regulatory recordCompanyPathwayDecision dateSource
Illumina, Inc.PMA approvalAug 21, 2024FDA

Explore the linked device profile

Other records with product code PQP

Product / regulatory recordCompanyPathwayDecision dateSource
Life Technologies CorporationPMA supplementNov 4, 2026FDA
xT CDxP210011/S006
Tempus AI, Inc.PMA supplementOct 23, 2026FDA
MI Cancer SeekP240010/S007
Caris Life SciencesPMA supplementOct 16, 2026FDA
Foundation Medicine, Inc.PMA supplementSep 18, 2026FDA
Guardant360 CDxP200010/S029
Guardant Health, Inc.PMA supplementSep 18, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Illumina, Inc.

Headquarters
Not reported
Brand website
illumina.com
FDA applicant address
5200 Illumina Way, San Diego, CA, 92122

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records